#1 Clinical Trials Search in Europe

Raltegravir

Raltegravir is an antiretroviral medication used in the treatment of HIV infection. This article examines several clinical trials that have investigated the safety, efficacy, and pharmacokinetics of raltegravir in different patient populations and treatment scenarios. The trials provide valuable insights into how raltegravir performs as part of combination antiretroviral therapy regimens for managing HIV.

Table of Contents

What is Raltegravir?

Raltegravir is an antiretroviral medication primarily used to treat Human Immunodeficiency Virus (HIV) infection. It is also known by its brand name Isentress® or by its research code MK-0518[1][2]. Raltegravir belongs to a class of drugs called integrase inhibitors, which work in a unique way to fight HIV infection[4].

How Does Raltegravir Work?

Raltegravir works by blocking an enzyme called integrase, which HIV uses to insert its genetic material into human cells. By inhibiting this process, Raltegravir prevents HIV from replicating and spreading in the body[4]. This mechanism of action is different from other types of HIV medications, making Raltegravir an important option for treating HIV, especially in cases where the virus has become resistant to other drugs[4].

What Conditions Does Raltegravir Treat?

Raltegravir is primarily used to treat:

  • HIV-1 Infection: This is the main use of Raltegravir. It is used in combination with other antiretroviral drugs to suppress the virus in patients with HIV[1][2].
  • AIDS (Acquired Immunodeficiency Syndrome): As AIDS is an advanced stage of HIV infection, Raltegravir is also used in its treatment[4].

Interestingly, some research is exploring the potential use of Raltegravir in other conditions:

  • Multiple Sclerosis: A pilot study investigated the use of Raltegravir in patients with relapsing-remitting multiple sclerosis. This research is based on the theory that certain viruses might play a role in multiple sclerosis[8].

Dosage and Administration

Raltegravir is typically taken orally in tablet form. The common dosages include:

  • 400 mg twice daily[1][2]
  • 1200 mg (two 600 mg tablets) once daily[6]

The specific dosage may vary depending on the individual patient’s needs and other medications they are taking. It’s important to take Raltegravir exactly as prescribed by your healthcare provider[1][2].

Efficacy of Raltegravir

Clinical trials have shown that Raltegravir is effective in treating HIV infection. Key findings include:

  • Reduction in HIV RNA levels (viral load) in the blood[4]
  • Increase in CD4 cell counts, which are important immune cells that HIV attacks[2]
  • Effectiveness in patients who have developed resistance to other antiretroviral drugs[4]

One study found that adding Raltegravir to an existing antiretroviral regimen helped maintain viral suppression in patients with undetectable HIV levels[5].

Safety and Side Effects

Raltegravir is generally well-tolerated, but like all medications, it can cause side effects. Common side effects may include:

  • Headache
  • Nausea
  • Diarrhea
  • Fatigue

More serious side effects are rare but can occur. These may include severe skin reactions or allergic reactions. It’s important to report any unusual symptoms to your healthcare provider[6].

Use in Special Populations

Raltegravir has been studied in various patient groups:

  • Patients with Liver Disease: One study investigated the use of Raltegravir in HIV patients with end-stage liver disease and in liver transplant recipients[3].
  • Older Adults: A study looked at the effectiveness of Raltegravir in HIV patients aged 50 years and older[2].
  • Japanese Patients: A study specifically examined the safety and pharmacokinetics of Raltegravir in healthy Japanese male participants[6].

Ongoing Research and Potential New Uses

Research on Raltegravir is ongoing, exploring its potential in various areas:

  • HIV Prevention: One study investigated the use of Raltegravir as part of a regimen for post-exposure prophylaxis (PEP) to prevent HIV infection after potential exposure[1].
  • Multiple Sclerosis: A pilot study explored the potential of Raltegravir in treating relapsing-remitting multiple sclerosis. This research is based on the theory that certain viruses might be involved in the development of multiple sclerosis[8].
  • Improving HIV Treatment: Studies are looking at how adding Raltegravir to existing HIV treatment regimens might help patients who have low-level viral persistence despite treatment[7].
Trial Name/ID Study Population Key Findings
NCT01022476 HIV patients with end-stage liver disease and transplant recipients Evaluated pharmacokinetics and drug interactions of raltegravir with immunosuppressants in liver transplant patients
NCT01213316 HIV-infected adults and older adults (≥50 years) Assessed efficacy of raltegravir in combination therapy; 48-week viral suppression and CD4 count increases observed
NCT00105157 HIV-infected patients failing current antiretroviral therapies Investigated safety and efficacy of different raltegravir doses; showed viral load reductions and CD4 count improvements
NCT01245101 HIV patients with poor immune restoration despite suppressive therapy Examined effects of adding raltegravir on immune activation and CD4 counts; results pending
NCT03667547 Healthy Japanese male participants Evaluated safety, tolerability, and pharmacokinetics of single 1200mg raltegravir dose
NCT00618371 HIV patients with low-level viremia on antiretroviral therapy Investigated if adding raltegravir reduced viral load further; no significant reductions observed

FAQ

  • What is raltegravir and how does it work? Raltegravir is an antiretroviral medication used to treat HIV infection. It works by blocking an enzyme called integrase that HIV needs to insert its genetic material into human cells. This prevents the virus from replicating and spreading in the body.
  • What types of patients were studied in the raltegravir clinical trials? The trials studied various groups including HIV-infected patients failing current antiretroviral therapies, patients with end-stage liver disease and transplant recipients, aging HIV patients over 50 years old, and patients with low-level HIV viremia despite treatment.
  • What were some of the main outcomes measured in these trials? Key outcomes included changes in HIV viral load, CD4 cell counts, safety/adverse events, pharmacokinetic parameters of raltegravir, and markers of immune activation. Some trials also looked at effects on liver function and cardiovascular risk.
  • Was raltegravir found to be effective in suppressing HIV? Yes, several trials showed raltegravir was effective at reducing HIV viral load when added to existing antiretroviral regimens. It helped achieve undetectable viral loads in many patients who had been failing previous treatments.
  • What were the main side effects or safety concerns with raltegravir? Raltegravir was generally well-tolerated. Common side effects included headache, nausea, and fatigue. The trials monitored for serious adverse events but did not find major safety issues. Long-term safety continues to be evaluated.

Ongoing Clinical Trials on Raltegravir

  • Study on Doravirine and Raltegravir for Maintaining Viral Control in HIV Patients with Low Viral Load

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France Italy Spain

  • Study Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany The Netherlands Poland Spain

  • Study on the Effects of Abacavir Sulfate and Etravirine in Pregnant Women with HIV

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Ireland The Netherlands Spain

Glossary

  • Antiretroviral therapy: Treatment using drugs that suppress or stop the replication of HIV virus in the body.
  • CD4 cell count: A measure of the number of CD4 T cells in the blood, which are important immune cells targeted and destroyed by HIV. Higher counts indicate a stronger immune system.
  • Viral load: The amount of HIV genetic material (RNA) in a blood sample, reported as copies per milliliter. Lower viral loads indicate better control of the virus.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized and eliminated by the body over time.
  • Integrase inhibitor: A class of antiretroviral drugs, including raltegravir, that block the HIV enzyme integrase to prevent the virus from inserting its genetic material into human cells.
  • Virologic response: The reduction in HIV viral load in response to treatment, often defined as achieving an undetectable viral load.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment or procedure.
  • Open-label study: A type of clinical trial where both researchers and participants know which treatment is being administered.
  • Placebo: An inactive substance used as a control in clinical trials to test the effectiveness of a drug.
  • Crossover study: A type of clinical trial where participants receive two or more treatments in sequence, allowing comparison of effects within the same individuals.

References

  1. https://clinicaltrials.gov/study/NCT00594646
  2. https://clinicaltrials.gov/study/NCT01213316
  3. https://clinicaltrials.gov/study/NCT01022476
  4. https://clinicaltrials.gov/study/NCT00105157
  5. https://clinicaltrials.gov/study/NCT01245101
  6. https://clinicaltrials.gov/study/NCT03667547
  7. https://clinicaltrials.gov/study/NCT00618371
  8. https://clinicaltrials.gov/study/NCT01767701